drugset / Trial / NCT03948763
A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study will determine the safety and tolerability and establish a preliminary recommended Phase 2 dose of V941(mRNA-5671/V941) as a monotherapy and in combination with pembrolizumab infusion.
Timeline
- Start
- 2019-06-26
- Primary completion
- 2022-08-25
- Completion
- 2022-08-25
Outcome
Outcome not reported
Stopped (Business): “Business Reasons”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | V941 | Unknown | 1 mg | Intramuscular |